Improving the understanding of how patients with non-dystrophic myotonia are selected for myotonia treatment with mexiletine (NaMuscla): outcomes of treatment impact using a European Delphi panel

Table 1 Characteristics of the responding panellists

Country	Role	Years’ experience managing patients with NDM	Number of patients with NDM registered in centre/hospital	Current NDM patients in expert care^a	Experience with mexiletine (NaMuscla)
France	Neurologist	> 15 years	> 50	11–20	Yes
UK	Neurologist^b	> 10 years	5–10	< 5	Yes
UK	Clinical geneticist	≥ 20 years	5–10	< 5	Yes
Denmark	Neurologist	≥ 20 years	> 50	21–50	Yes
UK	Neurologist	> 10 years	5–10	5–10	Yes
UK	Specialist nurse	1–5 years	11–20	11–20	Yes
UK	Neurologist	≥ 20 years	11–20	5–10	Yes
Germany	Neurologist	≥ 20 years	> 50	21–50	Yes

Only participants responding to at least Round 1 are included in this table
Key: NDM Non-dystrophic myotonia
^aPlease note that NDM is a rare disease, therefore the number of patients under the panel’s care at any one time is expected to be relatively low. Moreover, the number of patients currently under the care of our expert panel is a snapshot indicator of the experts’ experience with treating NDM. All experts have treated substantially more patients with NDM over the duration of their career
^bThis expert dropped out after completing Round 1

ISSN: 1471-2377